NASDAQ$GNPX
Genprex Inc · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
Genprex reported Q1 2026 revenue of $0 with a net loss of $4.5M and diluted loss per share of $0.64.
For the quarter ended March 31, 2026, Genprex had no revenue and reported a net loss of $4.5 million versus $4.0 million in Q1 2025. Diluted loss per share was $0.64 compared with $12.98 on a much smaller prior-year share count. R&D expense was $2.7 million and G&A $1.7 million. Other income was minimal at $32K.
- Pre-revenue net loss of $4.5M with R&D spend of $2.7M.
- Diluted loss per share was $0.64 on 7.0M weighted average shares.
- G&A expense was $1.7M as the company advanced gene-therapy programs.
- No collaboration or product revenue was recognized in the quarter.
- Cash runway depends on financing and clinical progress per MD&A.
Headline financials
Revenue & EPS history
Genprex · Revenue · Quarterly
$541
Forward guidance
Genprex does not issue quantitative financial guidance in the 10-Q and notes substantial capital needs to advance REQORSA and other oncology programs.
Tailwinds
- Other income provided a small offset to operating losses.
- Share count stabilization improved per-share loss comparability versus prior year.
Headwinds
- No revenue and ongoing R&D burn before potential approvals.
- Gene-therapy development timelines remain uncertain and capital intensive.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2026
+1.3%
Avg return
Earnings day
-2.6%
Avg return
5 days after
-15.3%
Avg return
30 days after
46%
13 / 28 earnings
Positive
+39.3%
Q2 2022
Best reaction
-21.5%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.5% | -3.0% | — | |
| Q4 2025 | +2.3% | -13.0% | -44.9% | |
| Q3 2025 | +7.0% | -19.3% | -31.4% | |
| Q2 2025 | -1.9% | -24.5% | +35.2% | |
| Q1 2025 | +2.2% | -10.5% | +13.4% | |
| Q4 2024 | +2.9% | -3.5% | -3.5% | |
| Q3 2024 | -21.5% | -34.9% | -44.5% | |
| Q2 2024 | -11.3% | -48.6% | -66.9% | |
| Q1 2024 | +5.0% | +6.7% | +1.3% | |
| Q4 2023 | -4.7% | +0.7% | -24.2% | |
| Q3 2023 | +13.5% | +7.9% | -2.6% | |
| Q2 2023 | -5.6% | -9.4% | -12.7% | |
| Q1 2023 | +1.4% | +14.8% | +1.9% | |
| Q4 2022 | -2.5% | -11.4% | -9.4% | |
| Q3 2022 | -2.9% | -7.9% | -16.5% | |
| Q2 2022 | +39.3% | +61.3% | +17.3% | |
| Q1 2022 | +14.4% | +10.6% | +7.6% | |
| Q4 2021 | -2.6% | -0.4% | -31.0% | |
| Q3 2021 | -4.8% | -15.9% | -37.2% | |
| Q2 2021 | -9.3% | -5.2% | +0.7% | |
| Q1 2021 | +6.6% | +12.4% | +5.4% | |
| Q4 2020 | -5.4% | -3.8% | -100.0% | |
| Q3 2020 | -0.6% | -0.3% | +3.5% | |
| Q2 2020 | -4.2% | +12.6% | -4.5% | |
| Q1 2019 | +0.0% | -2.2% | -24.4% | |
| Q3 2018 | -5.7% | -6.4% | -16.4% | |
| Q2 2018 | +2.8% | -2.1% | -21.7% | |
| Q1 2018 | +20.2% | +22.6% | -6.6% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro